×
About 1,594,110 results
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
https://doi.org/10.1056/NEJMoa1805762
The New England Journal of Medicine; Dimopoulos MA, Dytfeld D et. al.

Nov 7th, 2018 - The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. The immunomodulatory agent pomalidomide plus dexamethasone has been shown to be effective in patients with multiple myeloma that is refractory to lenalidomide and a proteasome inhibitor. Patients with multiple myeloma t...

Influenza and Tdap Vaccination Coverage Among Pregnant Women - United States, April 2018.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188122
MMWR. Morbidity and Mortality Weekly Report; Kahn KE, Black CL et. al.

Sep 27th, 2018 - Vaccinating pregnant women with influenza and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines can reduce the risk for influenza and pertussis for themselves and their infants. The Advisory Committee on Immunization Practices (ACIP) recommends that all women who are or might be pregnant during the influenza season receive influenza vaccine, which can be adminis...

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.
https://doi.org/10.1056/NEJMoa1800149
The New England Journal of Medicine; Chitnis T, Arnold DL et. al.

Sep 12th, 2018 - Treatment of patients younger than 18 years of age with multiple sclerosis has not been adequately examined in randomized trials. We compared fingolimod with interferon beta-1a in this population. In this phase 3 trial, we randomly assigned patients 10 to 17 years of age with relapsing multiple sclerosis in a 1:1 ratio to receive oral fingolimod at a dose of 0.5 mg per day (0.25 mg per day for ...

Safety and Side Effects of Rifampin versus Isoniazid in Children.
https://doi.org/10.1056/NEJMoa1714284
The New England Journal of Medicine; Diallo T, Adjobimey M et. al.

Aug 1st, 2018 - The treatment of latent infection with Mycobacterium tuberculosis is important in children because of their vulnerability to life-threatening forms of tuberculosis disease. The current standard treatment - 9 months of isoniazid - has been associated with poor adherence and toxic effects, which have hampered the effectiveness of the drug. In adults, treatment with 4 months of rifampin has been s...

A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus.
https://doi.org/10.1056/NEJMoa1803760
The New England Journal of Medicine; Fenske W, Refardt J et. al.

Aug 1st, 2018 - The indirect water-deprivation test is the current reference standard for the diagnosis of diabetes insipidus. However, it is technically cumbersome to administer, and the results are often inaccurate. The current study compared the indirect water-deprivation test with direct detection of plasma copeptin, a precursor-derived surrogate of arginine vasopressin. From 2013 to 2017, we recruited 156...

Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations.
https://doi.org/10.1053/j.gastro.2017.12.012
Gastroenterology Hadjiliadis D, Khoruts A et. al.

Dec 31st, 2017 - Improved therapy has substantially increased survival of persons with cystic fibrosis (CF). But the risk of colorectal cancer (CRC) in adults with CF is 5-10 times greater compared to the general population, and 25-30 times greater in CF patients after an organ transplantation. To address this risk, the CF Foundation convened a multi-stakeholder task force to develop CRC screening recommendatio...

Five-year results of brentuximab vedotin in patients with relapsed or refractory system...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746164
Blood Pro B, Advani R et. al.

Oct 4th, 2017 - This pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory (R/R) systemic anaplastic large cell lymphoma (ALCL). After a median observation period of approximately 6 years from first treatment, we examined the durability of remission, progression-free survival (PFS), overall survival (OS), and safety outcomes of patients treated o...

Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control.
https://doi.org/10.1056/NEJMoa1703309
The New England Journal of Medicine; Cardemil CV, Dahl RM et. al.

Sep 6th, 2017 - The effect of a third dose of the measles-mumps-rubella (MMR) vaccine in stemming a mumps outbreak is unknown. During an outbreak among vaccinated students at the University of Iowa, health officials implemented a widespread MMR vaccine campaign. We evaluated the effectiveness of a third dose for outbreak control and assessed for waning immunity. Of 20,496 university students who were enrolled ...

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk M...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620419
Blood Jabbour E, Short NJ et. al.

Aug 4th, 2017 - Hypomethylating agents (HMAs) improve survival in patients with higher-risk myelodysplastic syndromes (MDS) but are less well-studied in lower-risk disease. We compared the safety and efficacy of low-dose decitabine vs low-dose azacitidine in this group of patients. Adults with low- or intermediate 1-risk MDS or MDS/myeloproliferative neoplasm (MPN), including chronic myelomonocytic leukemia, a...

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Clas...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791843
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology; Chen R, Zinzani PL et. al.

Apr 25th, 2017 - Purpose Hodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24.1, leading to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2. Pembrolizumab, a programmed death 1-blocking antibody, demonstrated a high overall response rate (ORR) in patients with relapsed or refractory classic Hodgkin lymphoma (rrHL) in phase I testing. Methods KEYNOTE-087 ( ClinicalTrials.gov identifie...

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901965
The New England Journal of Medicine; Hochhaus A, Larson RA et. al.

Mar 8th, 2017 - Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses on the basis of more than 10 years of follow-up in patients with CML who were treated with imatinib as initial therapy. In this open-label, multicenter trial with crossover design, we randomly assigned patients with newly diagnosed C...

Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Gro...
https://doi.org/10.1200/JCO.2016.71.3289
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology; Bröckelmann PJ, Goergen H et. al.

Feb 27th, 2017 - Purpose Clinical characteristics, therapeutic approaches, and prognosis of late relapse (LR) in patients with classic Hodgkin lymphoma (cHL) are poorly understood. We performed a comprehensive analysis of LR of Hodgkin lymphoma (LR-HL). Methods To estimate the incidence of LR-HL, we retrospectively analyzed 6,840 patients with cHL included in the German Hodgkin Study Group trials HD7 to HD12. P...

Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529262
Arthritis Care & Research; George MD, Baker JF et. al.

Jan 27th, 2017 - The optimal timing of tumor necrosis factor antagonists before elective surgery is unknown. This study evaluated the association between infliximab timing and serious infection after elective hip or knee arthroplasty. A retrospective cohort study evaluated US Medicare patients with rheumatoid arthritis, inflammatory bowel disease, psoriasis, psoriatic arthritis, or ankylosing spondylitis who re...

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
https://doi.org/10.1056/NEJMoa1513257
The New England Journal of Medicine; Roberts AW, Davids MS et. al.

Dec 7th, 2015 - New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central to the survival of CLL cells. We conducted a phase 1 dose-escalation study of daily oral venetoclax in patients with relapsed or refractory CLL or small lymphocytic lymphoma...

FDA approves first generics of Gilenya
https://www.fda.gov/news-events/press-announcements/fda-approves-first-generics-gilenya
FDA

Dec 8th, 2019 - The U.S. Food and Drug Administration has approved three applications for first generics of Gilenya (fingolimod) capsules for the treatment of relapsing forms of multiple sclerosis (MS) in adult patients.

Hereditary Cancer Syndromes and Risk Assessment ACOG COMMITTEE OPINION, Number 793
https://journals.lww.com/greenjournal/Fulltext/2019/12000/Hereditary_Cancer_Syndromes_and_Risk_Assessment_.39.aspx
Obstetrics & Gynecology; ACOG

Nov 30th, 2019 - A hereditary cancer syndrome is a genetic predisposition to certain types of cancer, often with onset at an early age, caused by inherited pathogenic variants in one or more genes. Most hereditary cancer syndromes exhibit autosomal dominant inheritance. The most common hereditary cancer syndromes related to women’s cancer include hereditary breast and ovarian cancer syndrome, Lynch syndrome, Li...

Fasting Triglycerides & Glucose Index: A Useful Screening Test for Assessing Insulin Resistance in Patients Diagnosed with Rheumatoid Arthritis & Systemic Lupus Erythematosus
https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-019-0495-x
Diabetology & Metabolic Syndrome; Contreras-Haro B, et al

Nov 26th, 2019 - Insulin resistance (IR) is frequently observed in patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). In clinical practice, IR assessment is limited to a low proportion of patients due to cost and equipment and technical expertise requirements. The surrogate index of triglycerides and glucose (TyG index) has been validated in non-rheumatic populations, showing adequat...

Eastern Equine Encephalitis Virus — Another Emergent Arbovirus in the United States
https://www.nejm.org/doi/full/10.1056/NEJMp1914328
New England Journal of Medicine; David M. Morens, M.D. et. al.

Nov 24th, 2019 - Humans have always lived in intimate association with arthropods that transmit pathogens between humans or from animals to humans. About 700,000 deaths due to vectorborne diseases occur globally each year, according to World Health Organization estimates. In the summer and fall of 2019, nine U.S. states have reported 36 human cases (14 of them fatal) of one of the deadliest of these diseases: e...

FDA takes second action under international collaboration, approves new treatment option for patients with chronic lymphocytic leukemia
https://www.fda.gov/news-events/press-announcements/fda-takes-second-action-under-international-collaboration-approves-new-treatment-option-patients
FDA

Nov 24th, 2019 - Today, as part of Project Orbis, a collaboration with the Australian Therapeutic Goods Administration (TGA) and Health Canada, the U.S. Food and Drug Administration granted supplemental approval to Calquence (acalabrutinib) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This new approved indication for Calquence provides a new treatment ...

Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
https://www.atsjournals.org/doi/full/10.1164/rccm.201909-1874ST
American Journal of Respiratory and Critical Care Medicine; Payam Nahid et al

Nov 20th, 2019 - The American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America jointly sponsored this new practice guideline on the treatment of drug-resistant tuberculosis (DR-TB). The document includes recommendations on the treatment of multidrug-resistant TB (MDR-TB) as well as isoniazid-resistant but rifampin-suscept...